1. Home
  2. GTIM vs MRUS Comparison

GTIM vs MRUS Comparison

Compare GTIM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GTIM
  • MRUS
  • Stock Information
  • Founded
  • GTIM 1987
  • MRUS 2003
  • Country
  • GTIM United States
  • MRUS Netherlands
  • Employees
  • GTIM N/A
  • MRUS N/A
  • Industry
  • GTIM Restaurants
  • MRUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GTIM Consumer Discretionary
  • MRUS Health Care
  • Exchange
  • GTIM Nasdaq
  • MRUS Nasdaq
  • Market Cap
  • GTIM N/A
  • MRUS 2.7B
  • IPO Year
  • GTIM 1990
  • MRUS 2016
  • Fundamental
  • Price
  • GTIM $2.36
  • MRUS $43.01
  • Analyst Decision
  • GTIM
  • MRUS Strong Buy
  • Analyst Count
  • GTIM 0
  • MRUS 13
  • Target Price
  • GTIM N/A
  • MRUS $86.85
  • AVG Volume (30 Days)
  • GTIM 15.6K
  • MRUS 711.2K
  • Earning Date
  • GTIM 05-01-2025
  • MRUS 05-07-2025
  • Dividend Yield
  • GTIM N/A
  • MRUS N/A
  • EPS Growth
  • GTIM N/A
  • MRUS N/A
  • EPS
  • GTIM 0.21
  • MRUS N/A
  • Revenue
  • GTIM $145,491,000.00
  • MRUS $36,133,000.00
  • Revenue This Year
  • GTIM N/A
  • MRUS $37.72
  • Revenue Next Year
  • GTIM N/A
  • MRUS $48.47
  • P/E Ratio
  • GTIM $11.17
  • MRUS N/A
  • Revenue Growth
  • GTIM 5.49
  • MRUS N/A
  • 52 Week Low
  • GTIM $2.25
  • MRUS $37.77
  • 52 Week High
  • GTIM $3.45
  • MRUS $61.61
  • Technical
  • Relative Strength Index (RSI)
  • GTIM 42.90
  • MRUS 44.45
  • Support Level
  • GTIM $2.36
  • MRUS $39.00
  • Resistance Level
  • GTIM $2.49
  • MRUS $45.44
  • Average True Range (ATR)
  • GTIM 0.12
  • MRUS 2.61
  • MACD
  • GTIM -0.00
  • MRUS -0.82
  • Stochastic Oscillator
  • GTIM 27.50
  • MRUS 40.44

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Share on Social Networks: